PharmaShots | Incisive News in 3 Shots

Subscribe Now

U.S. FDA

Incyte's Opzelura (ruxolitinib) Receives the US FDA's Approval for the Treatment of Atopic Dermatitis

Incyte's Opzelura (ruxolitinib) Receives the US FDA's Approval for the Treatment of Atopic Dermatitis

September 22, 2021

Takeda's Exkivity (mobocertinib) Receives the US FDA's Approval as the First Oral Therapy for EGFR Exon20 Insertion+ NSCLC

Takeda's Exkivity (mobocertinib) Receives the US FDA's Approval as the First Oral Therapy for EGFR Exon20 Insertion+ NSCLC

September 16, 2021

Janssen's Invega Hafyera (paliperidone palmitate) Receives the US FDA's Approval for the Treatment of Schizophrenia

Janssen's Invega Hafyera (paliperidone palmitate) Receives the US FDA's Approval for the Treatment of Schizophrenia

September 2, 2021

Athena Bioscience's Qdolo (tramadol hydrochloride) Receives US FDA's NDA Approval for Oral Solution

Athena Bioscience's Qdolo (tramadol hydrochloride) Receives US FDA's NDA Approval for Oral Solution

September 1, 2020

Precision BioSciences Receives the US FDA's Fast Track Designation for PBCAR0191 to Treat Advanced B-cell Precursor Acute Lymphoblastic Leukemia

Precision BioSciences Receives the US FDA's Fast Track Designation for PBCAR0191 to Treat Advanced B-cell Precursor Acute Lymphobl...

August 20, 2020

AbbVie Receives US FDA Approval for Imbruvica plus Rituximab for the treatment of Waldenström's macroglobulinemia (WM)

AbbVie Receives US FDA Approval for Imbruvica plus Rituximab for the treatment of Waldenström's macroglobulinemia (WM)

August 28, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us